Peptidylprolyl Isomerase a Regulates DNA Damage Repair and Serves as a Prognostic Biomarker in Lung Adenocarcinoma
Li Zou, Bixin Ren, Ying Wan, Xin Wang, Ruichi Shen, Wenlang Zhu, Limin Jin, Qiliang Peng, Ye Tian · 2026
Read Peptidylprolyl Isomerase a Regulates DNA Damage Repair and Serves as a Prognostic Biomarker in Lung Adenocarcinoma by Li Zou, Bixin Ren, Ying Wan, Xin Wang, Ruichi Shen, Wenlang Zhu, Limin Jin, Qiliang Peng, Ye Tian (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13401659.txt.
Description
Li Zou and co-authors published a 2026 study of peptidylprolyl isomerase A, a protein-folding enzyme called PPIA, in lung adenocarcinoma, combining data mining with laboratory validation. They asked whether the protein drives the cancer's behaviour and predicts patient outcomes.
PPIA was overexpressed in tumour tissue and tied to shorter overall and progression-free survival. Its levels tracked with copy number changes, DNA methylation, methylation-enzyme activity, and RNA modification genes. Higher PPIA went with lower immune cell infiltration and lower immune gene expression, hinting at an immune-dampening role, and drug sensitivity analyses suggested it could predict treatment response. Because PPIA levels also tracked with DNA damage repair genes, the team ran cell experiments, which showed that knocking PPIA down makes cancer cells more sensitive to radiation.
Catalog record
| CREATOR | Li Zou, Bixin Ren, Ying Wan, Xin Wang, Ruichi Shen, Wenlang Zhu, Limin Jin, Qiliang Peng, Ye Tian |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |